{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-017579","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.431109+00:00","generated_at":"2026-06-15T04:08:58.650477+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"VYNE Therapeutics reports Q1 2023 net loss of $5.6M; VYN201 Phase 1b data expected Q3 2023","bullets":["Q1 2023 GAAP net loss $5.6M vs net income $4.7M in Q1 2022; loss from continuing ops improved to $5.6M from $8.7M.","Topline 16-week data for all three cohorts of VYN201 Phase 1b trial in vitiligo expected in Q3 2023.","Lead development candidate selected for VYN202 oral BD2-selective BET inhibitor; IND filing targeted by year-end 2023.","Positive safety and PK data from VYN201 Phase 1a; no serious adverse events or dose adjustments.","Preclinical data for inhaled VYN201 in IPF model showed anti-inflammatory and anti-fibrotic effects."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-017579","json":"https://secwatch.observer/filing/0001628280-23-017579.json","markdown":"https://secwatch.observer/filing/0001628280-23-017579.md","text":"https://secwatch.observer/filing/0001628280-23-017579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000162828023017579/0001628280-23-017579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000162828023017579/mnlo-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:08:58.650477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d47656a9bbdb43f53cb370f9ce357c39902a298","claim":"VYNE Therapeutics Inc. reported the three months ended March 31, 2023 results: net income $ (5,622).","evidence_excerpt":"1 Financial Performance (in thousands) Three Months Ended March 31 2023 2022 Loss from continuing operations (GAAP) $ (5,612) $ (8,694) Adjusted loss from continuing operations (non-GAAP)* $ (4,756) $ (7,449) Net (loss) income (GAAP) $ (5,622) $ 4,670 Adjusted net (loss) income (non-GAAP)* $ (4,766) $ 5,563 *See \"","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000162828023017579/0001628280-23-017579-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Net income","value":"$ (5,622)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}